TRex Bio, Inc. (TRXB)

Profile

https://trex.bio

TRex Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing immunoregulatory medicines for autoimmune and inflammatory diseases. The company’s work centers on tissue Treg biology, with a primary goal of restoring immune balance and supporting tissue repair through targeted therapies. Its current pipeline includes wholly owned product candidates such as TRB-061, a TNFR2 agonist designed to activate and expand regulatory T cells in inflamed tissues, and TRB-071, a CD30 agonist intended to modulate immune signaling pathways. TRex Bio’s research and development efforts are aimed at addressing treatment gaps in conditions where immune dysregulation drives chronic inflammation. Headquartered in South San Francisco, California, TRex Bio operates within the biotechnology sector and serves as a specialized developer of next-generation immune-based therapies.